Top Page
Micro-X Ltd.
(Sydney:MX1)
Micro-X Ltd. (MX1) vs. iShares MSCI Australia ETF (EWA)
Micro-X Ltd. Business Overview & Revenue Model
Micro-X Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.05M | 13.05M | 15.22M | 15.01M | 8.97M | 3.77M |
| Gross Profit | 5.98M | 10.32M | 5.74M | -7.11M | -12.33M | -12.96M |
| EBITDA | -15.70M | -11.76M | -14.35M | -15.54M | -19.02M | -13.61M |
| Net Income | -13.89M | -13.89M | -9.77M | -10.75M | -17.09M | -14.73M |
Balance Sheet | ||||||
| Total Assets | 22.11M | 22.11M | 26.89M | 30.30M | 31.28M | 44.68M |
| Cash, Cash Equivalents and Short-Term Investments | 3.24M | 3.24M | 3.23M | 5.22M | 10.30M | 30.14M |
| Total Debt | 6.53M | 6.53M | 3.99M | 4.70M | 5.31M | 5.84M |
| Total Liabilities | 14.56M | 14.56M | 12.63M | 13.17M | 12.05M | 10.53M |
| Stockholders Equity | 7.55M | 7.55M | 14.26M | 17.13M | 19.22M | 34.15M |
Cash Flow | ||||||
| Free Cash Flow | -8.69M | -8.69M | -6.80M | -11.77M | -19.22M | -10.76M |
| Operating Cash Flow | -8.59M | -8.59M | -6.43M | -10.99M | -18.11M | -9.86M |
| Investing Cash Flow | -100.00K | -100.00K | -369.00K | -779.00K | -1.11M | -901.00K |
| Financing Cash Flow | 8.71M | 8.71M | 4.81M | 6.69M | -612.00K | 22.57M |
Micro-X Ltd. Technical Analysis
Micro-X Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$25.13M | -2.62 | -103.74% | ― | 14.84% | 39.64% | |
50 Neutral | AU$110.03M | -8.20 | -31.98% | ― | 34.20% | -23.90% | |
47 Neutral | AU$2.47B | -64.88 | -44.49% | ― | 55.91% | 22.60% | |
44 Neutral | AU$172.40M | -16.13 | -70.55% | ― | ― | -257.32% | |
43 Neutral | AU$52.12M | -112.90 | -2.50% | ― | 25.72% | 84.69% | |
41 Neutral | AU$65.87M | -3.72 | -128.19% | ― | -14.25% | -22.83% |
Micro-X Ltd. Corporate Events
Micro-X Ltd has applied to the ASX for quotation of 37.25 million new fully paid ordinary shares under its existing issuer code MX1. The securities, issued on 24 December 2025 as part of a previously announced transaction, will expand the company’s quoted share base, signalling a capital-raising or structural move that may affect ownership dispersion and liquidity for existing and new shareholders.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has issued 37,250,000 fully paid ordinary shares at $0.08 per share, increasing its capital base through a placement conducted without a prospectus under the exemption provisions of the Corporations Act. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations and stated there is no undisclosed market-sensitive information that investors would reasonably require, signalling that the capital raising is being carried out within the standard regulatory framework and without hidden risks for existing or new shareholders.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Limited announced its plan to issue up to 77,250,000 new ordinary fully paid shares, with the proposed issuance date set for December 24, 2025. This move is expected to provide additional capital, likely supporting the company’s growth initiatives and strengthening its position in the competitive medical imaging technology sector, enhancing its appeal to stakeholders and investors.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. has announced a $6 million capital raising initiative aimed at advancing the commercialization of its technologies and achieving various near-term strategic goals. As part of the development, the company’s strategic partner will increase their stake to 8.5%, signaling strengthened collaborative engagement and potential benefits for stakeholders through enhanced industry positioning.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X has raised $6.18M in its latest placement to fund critical commercial and manufacturing activities. With participation from key strategic investor Billion Prima, which increased its shareholding to 8.6%, and commitments from its chairman, this funding targets scaling up production of X-ray tubes and generators, advancing medical imaging initiatives like the Head CT product, and supporting partnerships in the security asset sector.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. announced the results of its 2025 Annual General Meeting, where all resolutions were carried with significant majorities. The re-election of directors and the adoption of the remuneration report were among the key resolutions passed, reflecting strong shareholder support and confidence in the company’s strategic direction.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. has achieved significant commercial and technical milestones over the past year, including the development of a portable Head CT scanner and advancements in airport security technology. The company secured over $36 million in external funding, including a substantial contract from the US Government, and formed a co-development partnership in Asia. These achievements underscore Micro-X’s commitment to innovation and strategic growth, with a focus on expanding its product roadmap and enhancing its market presence in medical imaging and security technology.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. held its 2025 Annual General Meeting, where the CEO presented a summary of the company’s current position and future prospects. The presentation emphasized that while the information provided is based on reliable sources, it may not be exhaustive, and stakeholders should conduct their own assessments. The company clarified that the presentation does not constitute an offer for securities or investment advice, and highlighted the legal limitations regarding the distribution of its securities in the United States and other jurisdictions.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has reported significant achievements for the quarter ending September 2025, including securing its largest order to date with a $3.3 million purchase from the Malaysian Ministry of Health for Rover Plus units. This order marks a strategic expansion into Southeast Asia and highlights the company’s growing momentum in the healthcare market. Additionally, Micro-X is advancing its Head CT technology for stroke diagnosis, with upcoming trials in Australian hospitals and a world-first deployment in ambulances, supported by a $4.4 million government grant. These developments underscore Micro-X’s commitment to expanding its market presence and enhancing its product offerings.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd announced a delay in submitting an Appendix 3Y to the ASX due to an administrative oversight related to the issuance of shares to Non-Executive Director Ilona Meyer. The company reassures stakeholders that it has adequate arrangements to ensure future compliance with ASX Listing Rules. This announcement highlights Micro-X’s commitment to transparency and regulatory compliance, which is crucial for maintaining investor confidence and supporting its strategic initiatives in expanding its market presence.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. has announced its 2025 Annual General Meeting, which will be held virtually on November 11, 2025. Shareholders are encouraged to participate via Zoom, with voting facilitated through an online platform. The meeting will cover various resolutions, and shareholders are advised to submit proxy votes in advance to ensure their participation in case of technical issues. This virtual meeting format underscores the company’s commitment to accessibility and engagement with its stakeholders.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd., a leader in cold cathode X-ray technology, announced it received a $5.08 million R&D Tax Incentive from the Australian Tax Office for the financial year ending June 2025. This rebate, which supports the company’s R&D activities, was used to repay a previously accessed funding facility. Micro-X is also seeking an additional $0.31 million through an amendment, potentially increasing the total R&D rebate to $5.39 million. This financial boost aligns with the company’s guidance and supports its ongoing innovation in health and security markets, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has announced a significant $3.3 million order from the Malaysian Ministry of Health for its Rover Plus Mobile DR X-ray units, marking its first major order in Southeast Asia. This order, facilitated by the newly appointed Malaysian distributor Integrated Medical System Sdn Bhd, is a key milestone in Micro-X’s expansion strategy in the region. The delivery of these units is set to begin in October 2025, reinforcing the company’s position in the global market for mobile X-ray solutions. This development not only highlights the growing international recognition of Micro-X’s technology but also underscores the company’s strategy of partnering with experienced local distributors to accelerate market adoption.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has reached a significant milestone with its Head CT scanner, completing the first imaging test system ready for installation in Australian hospitals. This development marks a crucial step in a pivotal study comparing Head CT images with conventional CT scans for stroke diagnosis, potentially transforming stroke care by enabling rapid point-of-care diagnosis in ambulances. The company has developed advanced technologies, including miniature NEX Technology tubes and novel image reconstruction software, and is collaborating with the Australian Stroke Alliance and other partners. The successful deployment of this technology could revolutionize stroke treatment by allowing prehospital deployment in ambulances, thus moving the hospital to the patient and reducing disability.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.